Fig. 2From: Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrheaImprovement in symptoms of each chief complaint that patients had before administration of the study drugBack to article page